7-Aug-2026
BOCOM International Holdings Company Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
TipRanks (Sun, 9-Aug 10:35 AM ET)
BeOne Medicines Ltd (6160) Gets a Buy from CICC
TipRanks (Fri, 7-Aug 8:35 PM ET)
UOB Kay Hian Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
TipRanks (Fri, 7-Aug 8:26 PM ET)
Bank of America Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
TipRanks (Fri, 7-Aug 8:25 PM ET)
Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC) and Doximity (DOCS)
TipRanks (Fri, 7-Aug 12:40 PM ET)
UBS Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
TipRanks (Thu, 6-Aug 8:26 PM ET)
CLSA Remains a Buy on BeOne Medicines Ltd (6160)
TipRanks (Thu, 6-Aug 8:26 PM ET)
TipRanks (Thu, 6-Aug 7:50 AM ET)
Wells Fargo Remains a Buy on BeOne Medicines (ONC)
TipRanks (Thu, 6-Aug 7:17 AM ET)
Guggenheim Sticks to Its Buy Rating for BeOne Medicines (ONC)
TipRanks (Thu, 6-Aug 6:57 AM ET)
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of August 7, 2026, ONC stock price climbed to $348.27 with 577,137 million shares trading.
ONC has a beta of 1.09, meaning it tends to be more sensitive to market movements. ONC has a correlation of 0.11 to the broad based SPY ETF.
ONC has a market cap of $38.74 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $2 billion in Revenue and $3.84 earnings per share. This beat revenue expectation by $114 million and exceeded earnings estimates by $2.40.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, CGIE, BBH.
ONC has underperformed the market in the last year with a return of +16.8%, while SPY returned +23.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ONC shares. However, ONC has outperformed the market in the last 3 month and 2 week periods, returning +9.9% and +6.9%, while SPY returned +6.0% and +4.6%, respectively. This indicates ONC has been having a stronger performance recently.
ONC support price is $323.11 and resistance is $336.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.